Signal Transduction and Targeted Therapy

SJR Rank #25H-index: 224SJR: 17.740Best quartile: Q1Open AccessAPC: US$3,790Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

Springer Nature

Country

United Kingdom

Type

journal

SJR by Edition

2022202505101520

Subject Categories

  • Cancer ResearchQ1
  • GeneticsQ1

Areas: Biochemistry, Genetics and Molecular Biology

Most published research topics

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCancer Immunotherapy and BiomarkersRNA modifications and cancerCAR-T cell therapy researchImmune Cell Function and InteractionEpigenetics and DNA MethylationImmune cells in cancerImmunotherapy and Immune ResponsesCancer, Hypoxia, and Metabolism

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs035070010501400

Documents per Year

202220250150300450600

Detailed Information

ISSN

2059-3635, 2095-9907

SJR Best Quartile

Q1

Region

Western Europe

Citations per Document (2 years)

51.26

References per Document

136.65

Coverage

2016-2026

Scope

Signal Transduction and Targeted Therapy is an international, peer-reviewed, open-access journal that publishes original research articles and review articles related to all aspects of signal transduction in physiological and pathological processes, as well as signal transduction-targeted therapeutics in the form of biological agents and small molecular drugs used to treat human diseases such as cancer, autoimmune disorders, and others. This journal focuses on cutting-edge advances both experimentally and clinically.

Metrics from SCImago Journal Rank 2025. View on SCImago